Avrobio Inc (NAS:AVRO)
$ 16.8 -0.02 (-1.41%) Market Cap: 62.85 Mil Enterprise Value: -27.41 Mil PE Ratio: 2.03 PB Ratio: 0.71 GF Score: 22/100

AVROBIO Inc Virtual Gaucher Disease Program Update Transcript

Dec 07, 2022 / 01:00PM GMT
Release Date Price: $9.38 (-6.96%)
Operator

Good morning, and welcome to the AVROBIO virtual Gaucher Disease Program Update. (Operator Instructions) And now I would like to turn the presentation over to Geoff MacKay, President and CEO of AVROBIO.

Geoff MacKay
AVROBIO, Inc. - Co- Founder, President, CEO & Director

Good morning. We're excited to share today a comprehensive update on our Gaucher disease program, including clinical and regulatory progress. You'll also meet Ariana, shown here, a 9-year-old living with Gaucher disease type 3 alongside her mom, a full-time caregiver, Veronica. Ariana is confined to a wheelchair on a ventilator and fed through a feeding tube and continues to progress despite treatment. The question that we asked ourselves when we first founded AVROBIO, is what if 1 gene could change your entire world. Our company is determined to develop a better solution, a single infusion gene therapy with the goal of altering the downward trajectory of debilitating genetic disease.

Before we begin today's update, I need to review our safe harbor statement. Today's discussion

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot